Results 101 to 110 of about 72,644 (316)

Malignant pleural mesothelioma with resolution of pleural effusion

Respirology Case Reports, 2023
Key message In malignant pleural mesothelioma patients, pleural effusion may improve during the course of the disease. Pleural effusion with nodular shadows bordering the pleura should be followed up even if the pleural effusion improves.
Sayaka Nishida, Kazutoshi Toriyama, Makiko Yomota, Yukio Hosomi   +3 more
doaj   +1 more source

The G protein‐coupled receptor GPR89A is a novel potential therapeutic target to overcome cisplatin resistance in NSCLC Calu1 cells

The FEBS Journal, EarlyView.
A genome‐wide CRISPR‐Cas9‐based genetic screen in cisplatin‐resistant NSCLC cells revealed 63 potential candidate genes for overcoming cisplatin resistance, including GPR89A. GPR89A, localised in the Golgi, modulates voltage‐gated anion channel activity and is involved in intracellular pH reduction.
Hale Guler Kara, Eda Dogan, Vildan Bozok, Cagdas Aktan, Ece Cakiroglu, Zuhal Eroglu, Duygu Aygunes Jafari, Kemal Sami Korkmaz, Serif Senturk, Buket Kosova   +9 more
wiley   +1 more source

Anti-Tumor Effects of TRAIL-Expressing Mesenchymal Stromal Cells in a Mouse Xenograft Model of Human Mesothelioma [PDF]

, 2015
Malignant mesothelioma (MM) remains a highly deadly malignancy with poor treatment option. The MM cells further promote a highly inflammatory microenvironment which contributes to tumor initiation, development, severity, and propagation. We reasoned that
Janes, SM, Sage, E
core  

Current and prospective pharmacotherapies for the treatment of pleural mesothelioma [PDF]

, 2017
Introduction: Mesothelioma is a rare asbestos-linked cancer with an expected incidence peak between 2015–2030. Therapies remain ineffective, thus developing and testing novel treatments is important for both oncologists and researchers. Areas covered:
Aoe K, Della Pepa C, Doyle C, Dudek AZ, Flores RM, Fujimoto N, Garland LL, Ismail-Khan R, Janne PA, Kalra N, Kurai J, Leigh RA, Neumann V, Pache JC, Papa S, Papaspyros S, Porpodis K, Ramalingam SS, Sterman DH, Suzuki Y, Zarogoulidis P   +20 more
core   +2 more sources

Loss of MTAP expression is not an accurate surrogate for CDKN2A homozygous deletions in peritoneal mesothelioma

Histopathology, EarlyView.
MTAP immunohistochemistry (IHC) was evaluated as a diagnostic tool for peritoneal mesothelioma by comparing it with CDKN2A homozygous deletion (HD) detected by FISH. Results showed low concordance between MTAP IHC and CDKN2A HD, suggesting MTAP IHC is not reliable for predicting CDKN2A HD in peritoneal mesothelioma. Further studies are needed.
Andrea Quaranta, Andrea Marzullo, Francesco Fortarezza, Sonia Maniglio, Concetta Caporusso, Floriana Pentimone, Federica Pezzuto, Domenica Cavone, Teresa Lettini, Mario Magistro, Cecilia Salzillo, Luigi Vimercati, Paolo Graziano, Gabriella Serio, Antonio d'Amati   +14 more
wiley   +1 more source

Reproducibility of histological subtyping of malignant pleural mesothelioma [PDF]

, 2014
Malignant pleural mesothelioma (MPM) has a very poor prognosis. Although clinical stage is currently the only reliable prognostic factor, histologic subtyping reportedly also affects prognosis.
Brčić, Iva, Brčić, Luka, Jakopović, Marko, Klarić, Vlasta, Milošević, Milan, Samaržija, Miroslav, Seiwerth, Sven, Šepac, Ana   +7 more
core   +1 more source

Factors influencing malignant mesothelioma survival: a retrospective review of the National Mesothelioma Virtual Bank cohort [version 2; referees: 1 approved, 2 approved with reservations]

F1000Research, 2018
Background: Malignant mesothelioma (MM) is a rare but deadly malignancy with about 3,000 new cases being diagnosed each year in the US.  Very few studies have been performed to analyze factors associated with mesothelioma survival, especially for ...
Waqas Amin, Faina Linkov, Douglas P. Landsittel, Jonathan C. Silverstein, Michael J. Becich   +4 more
doaj   +1 more source

Expression of Heart Development Protein With EGF‐Like Domains 1 (HEG1) Decorated With Low‐Sulfated Keratan Sulfate in Human Malignant Pleural Mesothelioma

Pathology International, EarlyView.
The purpose of this study is to investigate sulfation modification of the glycan structure decorating HEG1, one of the diagnostic markers of malignant pleural mesothelioma (MPM), in MPM. Immunohistochemical analysis reveals low‐sulfated keratan sulfate (KS) expression, recognized by 294‐1B1 and R‐10G, in MPM tissues with HEG1 expression.
Koki Nakashima, Hitomi Hoshino, Zui Zhang, Tomoya O. Akama, Nobuyuki Kondo, Seiki Hasegawa, Yoshitaka Sekido, Mana Fukushima, Tamotsu Ishizuka, Motohiro Kobayashi   +9 more
wiley   +1 more source

New Perspectives on Diagnosis and Therapy of Malignant Pleural Mesothelioma

Frontiers in Oncology, 2018
Malignant pleural mesothelioma (MPM) is a rare, but severe form of cancer, with an incidence that varies significantly within and among different countries around the world.
Marika Rossini, P. Rizzo, I. Bononi, A. Clementz, R. Ferrari, F. Martini, M. Tognon   +6 more
semanticscholar   +1 more source

Surgery for malignant pleural mesothelioma [PDF]

Expert Review of Respiratory Medicine, 2010
The role of surgery for malignant pleural mesothelioma encompasses the need for rapid diagnosis, preoperative staging and surgical resection, and also the need for a greater biological understanding of this rare and aggressive malignancy. In the multimodality treatment paradigm, the goal of surgery is to provide a macroscopic complete resection (i.e ...
Andrea S. Wolf, David J. Sugarbaker
openaire   +3 more sources